Abstract 365P
Background
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Malaysia and the incidence rate is high in the state of Sabah. Patients in Sabah are known to have limitations to access the healthcare services in the state. The purpose of this study is to examine the survival results, failure patterns, and compliance rate of patients with nasopharyngeal cancer who received radical radiotherapy with or without chemotherapy in Sabah.
Methods
A retrospective analysis was performed on patients diagnosed with stage I-IVA (AJCC staging 8th edition) NPC and treated with radiotherapy between the years of 2017-2019 in Sabah Women and Children's Hospital. The Kaplan-Meier method was used for survival analysis and differences in survival according to AJCC stage was compared using the log-rank test.
Results
A total of 140 patients were treated during this period. Most of them presented late at diagnosis, stage III (39%) and stage IVA (40%). Majority of them were treated with IMRT technique (85%). The compliance rate to radiotherapy was 96%. The 3-year overall survival (OS), disease-free-survival (DFS), local-failure-free survival (LFFS), regional-failure-free survival (RFFS), distant-failure-free survival (DFFS), of NPC patients in this study are 70%, 61%, 83%, 84%, and 67% respectively. The LFFS was significantly different between T stages (P value = 0.003) and T4 stage had the lowest rate of 3-year LFFS (65%). The RFFS was significantly different between N stages (P value = 0.013) and the 3-year RFFS probability for N3 stage was markedly lower than the rest (63%). The DFFS was significantly different between N stages (P-value < 0.001) and the 3-year DFFS probability decreased as N stage increased.
Conclusions
The 3-year OS and 3-year DFS rates in our study are comparable to those in peninsular Malaysia. The LFFS for T1-T3 stages is high. However, LFFS is low in T4 disease and DFFS is significantly low in N3 disease. Hence prospective studies are needed to determine if this group of patients may benefit from an intensified systemic treatment. Despite facing many challenges to access healthcare in Sabah, NPC patients in the state have a remarkably high compliance rate to radiotherapy treatment.
Clinical trial identification
NMRR ID-23-00055-E3N; RSCH ID-22-02599-GSk.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract